Please login to the form below

Not currently logged in
Email:
Password:

anti-NGF

This page shows the latest anti-NGF news and features for those working in and with pharma, biotech and healthcare.

FDA halts study of Teva and Regeneron's pain drug fasinumab

FDA halts study of Teva and Regeneron's pain drug fasinumab

Arthropathy has been seen before with NGF inhibitors - and caused the agency to put the entire class under a clinical hold in 2011. ... Eli Lilly and partner Pfizer also remain in the race with their tanezumab anti-NGF candidate, which restarted testing

Latest news

  • Regeneron says anti-NGF fasinumab works in pain Regeneron says anti-NGF fasinumab works in pain

    Regeneron says anti-NGF fasinumab works in pain. Clinical trial shows promise for opioid alternative. ... The decision was attributed to shifting commercial priorities rather than a safety or efficacy issue, but added to the anxiety among anti-NGF

  • Lilly eyes pivotal trials for pain drug tanezumab in 2015 Lilly eyes pivotal trials for pain drug tanezumab in 2015

    The antibody drug targets nerve growth factor (NGF) and - if approved - would represent a completely new drug class for chronic pain conditions, including osteoarthritis and cancer-related pain. ... In 2012 however a new partial clinical hold on the

  • J&J chief predicts 10 new pharma filings by 2017 J&J chief predicts 10 new pharma filings by 2017

    Among the pipeline projects highlighted by Gorsky are esketamine, a glutamate NMDA antagonist that he described as a "potential breakthrough medication" for treatment-resistant depression, as well as anti-CD38 antibody ... Fulranumab, an anti-nerve

  • Pfizer sales down but oncology shows promise Pfizer sales down but oncology shows promise

    There were also gains for anti-inflammatory Celebrex (celecoxib), up 11 per cent to $752m, while fibromyalgia drug Lyrica (pregabalin) cemented its position as Pfizer's biggest-selling product with a ... The company has also joined forces with Lilly to

More from news
Approximately 1 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Consulting at McCann Health

We are the strategic consultancy of McCann Health. We combine fresh and creative thinking with scientific and strategic depth...

Latest intelligence

PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....

Infographics